- Home
- DTE vs BIIB Comparison
DTE vs BIIB Comparison
Compare DTE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTE | BIIB |
|---|---|---|
| Founded | 1903 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.2B | 27.1B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | DTE | BIIB |
|---|---|---|
| Price | $149.31 | $185.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 27 |
| Target Price | $150.08 | ★ $194.72 |
| AVG Volume (30 Days) | ★ 1.2M | 743.5K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.39 | N/A |
| P/E Ratio | ★ $20.29 | $21.05 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $123.69 | $110.04 |
| 52 Week High | $154.63 | $202.41 |
Technical Indicators
Market Signals| Indicator | DTE | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 48.56 |
| Support Level | $132.67 | $170.99 |
| Resistance Level | $150.31 | $190.20 |
| Average True Range (ATR) | 2.34 | 5.04 |
| MACD | -0.34 | -1.05 |
| Stochastic Oscillator | 79.19 | 33.70 |
Price Performance
Historical ComparisonAbout DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).